Arzoxifene: the evidence for its development in the management of breast cancer.

ABSTRACT:

Introduction

Endocrine therapy is an important and integral part of breast cancer management. Selective estrogen receptor modulators (SERMs), such as tamoxifen, remain a vital component in the endocrine therapy armamentarium. However the "ideal SERM", which has antagonist effects on the breast and endometrium but beneficial agonistic effects on bone and lipid profile, remains to be found.

Aim

The aim of this review is to examine the evidence for arzoxifene as the "ideal SERM."

Evidence review

Arzoxifene showed initial promise as the "ideal SERM" in preclinical, phase I, and phase II clinical studies. It appeared to have powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile, minimal

SUBMITTER: Jackson LR 

PROVIDER: S-EPMC3012444 | biostudies-literature | 2008 Jul

REPOSITORIES: biostudies-literature